Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Metabolic programming and immune suppression in the tumor microenvironment
Increased glucose metabolism and uptake are characteristic of many tumors and used
clinically to diagnose and monitor cancer progression. In addition to cancer cells, the tumor …
clinically to diagnose and monitor cancer progression. In addition to cancer cells, the tumor …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Clinical implications of T cell exhaustion for cancer immunotherapy
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
CAR T-cell therapy in autoimmune diseases
Despite the tremendous progress in the clinical management of autoimmune diseases,
many patients do not respond to the currently used treatments. Autoreactive B cells play a …
many patients do not respond to the currently used treatments. Autoreactive B cells play a …
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
The success of chimeric antigen receptor (CAR) T cell therapy in treating several
hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of …
hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of …
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …
Challenges and new technologies in adoptive cell therapy
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
L Amini, SK Silbert, SL Maude, LJ Nastoupil… - Nature Reviews …, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …
patients with certain haematological cancers, with multiple CAR T cell products currently …